Prostate cancer medicine hailed as a "milestone" breakthrough may not be available to every patient after a revision of the drug guidelines, according to the NHS.
Men in England who have already been treated with a new-generation cancer drug would not be eligible for Enzalutamide, according to the National Institute for Health and Care Excellence (Nice).
Nice, the public body which decides the cost-effectiveness of medicines for NHS patients, said the new drug should not be used by patients who had already taken abiraterone.
Enzalutamide blocks molecular signals driving prostate cancer and improved survival by 30% in men who had not undergone chemotherapy.
A further 80% of men with advanced cancer had the progression delayed, even if the tumour had failed to respond to other treatments.
More top news
So-called legal highs are set to be banned en masse. But what are they, and why is this drastic move necessary?
The Swiss 79-year-old joined Fifa in 1975, with his reign as president starting in 1998. But who is he?
85% of products surveyed by the charity Action on Sugar were found to have more of the sweet stuff than Haribo.